CN101959519B - 用于玻璃体内注射的低粘度、高度絮凝的曲安奈德混悬液 - Google Patents

用于玻璃体内注射的低粘度、高度絮凝的曲安奈德混悬液 Download PDF

Info

Publication number
CN101959519B
CN101959519B CN2009801076823A CN200980107682A CN101959519B CN 101959519 B CN101959519 B CN 101959519B CN 2009801076823 A CN2009801076823 A CN 2009801076823A CN 200980107682 A CN200980107682 A CN 200980107682A CN 101959519 B CN101959519 B CN 101959519B
Authority
CN
China
Prior art keywords
suspension composite
suspension
composite
chloride
triamcinolone acetonide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN2009801076823A
Other languages
English (en)
Chinese (zh)
Other versions
CN101959519A (zh
Inventor
B·P·卡布拉
R·萨卡
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Alcon Research LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Research LLC filed Critical Alcon Research LLC
Publication of CN101959519A publication Critical patent/CN101959519A/zh
Application granted granted Critical
Publication of CN101959519B publication Critical patent/CN101959519B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
CN2009801076823A 2008-03-11 2009-03-10 用于玻璃体内注射的低粘度、高度絮凝的曲安奈德混悬液 Active CN101959519B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3545908P 2008-03-11 2008-03-11
US61/035,459 2008-03-11
PCT/US2009/036652 WO2009114521A1 (en) 2008-03-11 2009-03-10 Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection

Publications (2)

Publication Number Publication Date
CN101959519A CN101959519A (zh) 2011-01-26
CN101959519B true CN101959519B (zh) 2013-03-20

Family

ID=40548758

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801076823A Active CN101959519B (zh) 2008-03-11 2009-03-10 用于玻璃体内注射的低粘度、高度絮凝的曲安奈德混悬液

Country Status (21)

Country Link
US (3) US8128960B2 (enExample)
EP (1) EP2262506B1 (enExample)
JP (1) JP5581227B2 (enExample)
KR (1) KR101555293B1 (enExample)
CN (1) CN101959519B (enExample)
AR (1) AR070824A1 (enExample)
AU (1) AU2009223649B2 (enExample)
BR (1) BRPI0909630B8 (enExample)
CA (1) CA2717605C (enExample)
CL (1) CL2009000573A1 (enExample)
DK (1) DK2262506T3 (enExample)
ES (1) ES2471122T3 (enExample)
MX (1) MX2010009974A (enExample)
PL (1) PL2262506T3 (enExample)
PT (1) PT2262506E (enExample)
RU (1) RU2481842C2 (enExample)
SI (1) SI2262506T1 (enExample)
TW (1) TWI468165B (enExample)
UY (1) UY31699A1 (enExample)
WO (1) WO2009114521A1 (enExample)
ZA (1) ZA201005839B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070202186A1 (en) 2006-02-22 2007-08-30 Iscience Interventional Corporation Apparatus and formulations for suprachoroidal drug delivery
DK2262506T3 (da) * 2008-03-11 2014-06-10 Alcon Res Ltd Meget flokkulerede triamcinolonacetonid-suspensioner med lav viskositet til intravitreal injektion
RU2011130552A (ru) * 2008-12-22 2013-01-27 Алькон Рисерч, Лтд. Композиции местных глазных растворов для доставки эффективных концентраций активного агента в задний сегмент глаза
CN103327939B (zh) 2010-10-15 2017-05-24 科尼尔赛德生物医学公司 用于进入眼睛的装置
CN102008488B (zh) * 2010-11-24 2012-10-10 广州固志医药科技有限公司 一种曲安奈德眼用制剂及其制备方法
AR090775A1 (es) * 2012-04-23 2014-12-03 Otsuka Pharma Co Ltd Preparado inyectable
ES3023054T3 (en) * 2012-11-08 2025-05-29 Clearside Biomedical Inc Methods for the treatment of ocular disease in human subjects
MX372859B (es) 2013-05-03 2020-07-07 Clearside Biomedical Inc Aparatos y métodos para inyección ocular.
EP3003454B1 (en) 2013-06-03 2020-01-08 Clearside Biomedical, Inc. Apparatus for drug delivery using multiple reservoirs
RU2710491C2 (ru) 2014-06-20 2019-12-26 Клиасайд Байомедикал, Инк. Устройство для инъекции лекарственного средства в глазную ткань и способ инъекции лекарственного средства в глазную ткань
US9694145B1 (en) 2016-03-29 2017-07-04 Joseph Onorato Auto-injector systems and method for delivering cyst medication on demand
CA3062845A1 (en) 2016-05-02 2017-11-09 Clearside Biomedical, Inc. Systems and methods for ocular drug delivery
IL305537B2 (en) 2016-08-12 2025-02-01 Clearside Biomedical Inc Devices and methods for adjusting the insertion depth of a needle for administering a drug
WO2018204515A1 (en) 2017-05-02 2018-11-08 Georgia Tech Research Corporation Targeted drug delivery methods using a microneedle
WO2019136512A1 (en) * 2018-01-10 2019-07-18 Eye Co Pty Ltd Medical device and pharmaceutical composition for treatment of an eye disease or condition
USD893715S1 (en) 2018-11-06 2020-08-18 Joseph Onorato Measurement guide for a cyst, lesion or skin disorder
TW202103707A (zh) * 2019-04-16 2021-02-01 美商克利爾斯德生物醫學公司 注射用安西諾隆（ｔｒｉａｍｃｉｎｏｌｏｎｅ）調配物
US10814001B1 (en) 2019-05-06 2020-10-27 Rvl Pharmaceuticals, Inc. Oxymetazoline compositions
CN114010593A (zh) * 2021-11-23 2022-02-08 莱默(北京)药业科技有限公司 一种曲安奈德混悬注射液及制备方法
CN115969784B (zh) * 2022-12-26 2025-10-21 昆明积大制药股份有限公司 曲安奈德注射液的制备方法
WO2025114562A1 (en) * 2023-11-30 2025-06-05 Institut National de la Santé et de la Recherche Médicale Intravitreal spironolactone suspension

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005107705A2 (en) * 2004-04-30 2005-11-17 Allergan, Inc. Extended therapeutic effect ocular implant treatments
CN1852700A (zh) * 2003-09-23 2006-10-25 爱尔康公司 曲安奈德和醋酸阿奈可他注射用制剂
CN101119733A (zh) * 2005-02-18 2008-02-06 参天制药株式会社 减轻或避免甾族化合物副作用的方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3962430A (en) * 1974-08-07 1976-06-08 Merck & Co., Inc. Sterilization of solid non-electrolyte medicinal agents employing sodium chloride
US4370325A (en) * 1979-03-30 1983-01-25 Dermik Laboratories Pharmaceutical compositions and method of treatment
US4432964A (en) * 1981-08-24 1984-02-21 Alza Corporation Topical composition containing steroid in two forms released independently from polymeric carrier
US5164190A (en) * 1990-12-11 1992-11-17 Theratech, Inc. Subsaturated transdermal drug delivery device exhibiting enhanced drug flux
US5770589A (en) 1993-07-27 1998-06-23 The University Of Sydney Treatment of macular degeneration
AU4472396A (en) 1994-12-30 1996-07-24 American Home Products Corporation Clear non-alcoholic hydrocortisone solutions
CA2336703A1 (en) 1998-07-10 2000-01-20 The University Of Sydney Prophylactic treatments of neovascularisation in macular degeneration
AR026073A1 (es) 1999-10-20 2002-12-26 Nycomed Gmbh Composicion farmaceutica acuosa que contiene ciclesonida
AUPQ496500A0 (en) 2000-01-06 2000-02-03 University Of Sydney, The Kit
US6395294B1 (en) 2000-01-13 2002-05-28 Gholam A. Peyman Method of visualization of the vitreous during vitrectomy
US6656505B2 (en) * 2000-07-21 2003-12-02 Alpharma Uspd Inc. Method for forming an aqueous flocculated suspension
US20030195179A1 (en) * 2000-08-25 2003-10-16 Shirou Sawa Aqueous suspension preparations
SG152907A1 (en) * 2001-07-09 2009-06-29 Combinatorx Inc Combinations for the treatment of inflammatory disorders
US20030129242A1 (en) 2002-01-04 2003-07-10 Bosch H. William Sterile filtered nanoparticulate formulations of budesonide and beclomethasone having tyloxapol as a surface stabilizer
WO2004073607A2 (en) 2003-02-20 2004-09-02 Alcon, Inc. Use of steroids to treat ocular disorders
US20040186084A1 (en) 2003-03-21 2004-09-23 Akorn, Inc. Triamcinolone formulations and methods for their preparation and use
US20070224278A1 (en) 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
US20050101582A1 (en) 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
US20060141049A1 (en) 2003-11-12 2006-06-29 Allergan, Inc. Triamcinolone compositions for intravitreal administration to treat ocular conditions
JP2007516297A (ja) * 2003-12-23 2007-06-21 アルザ・コーポレーシヨン 制御送達用薬剤組成物の溶解度を高くする方法および投薬形態物
AU2005209201B2 (en) 2004-01-20 2010-06-03 Allergan, Inc. Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
CN1964723B (zh) 2004-05-31 2011-06-22 千寿制药株式会社 大分子化合物的细颗粒在制造透明组织可视化制剂中的应用
US8246949B2 (en) 2004-10-27 2012-08-21 Aciont, Inc. Methods and devices for sustained in-vivo release of an active agent
WO2006055954A2 (en) 2004-11-17 2006-05-26 Government Of The U.S.A., As Represented By The Secretary, Department Of Health & Human Services Steroid formulation and methods of treatment using same
US7893040B2 (en) * 2005-07-22 2011-02-22 Oculis Ehf Cyclodextrin nanotechnology for ophthalmic drug delivery
ITRM20050547A1 (it) 2005-11-04 2007-05-05 Sooft Italia S R L Gel oftalmico composto da triamcinolone acetonide e da un polimero poliacrilico.
DK2262506T3 (da) * 2008-03-11 2014-06-10 Alcon Res Ltd Meget flokkulerede triamcinolonacetonid-suspensioner med lav viskositet til intravitreal injektion

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1852700A (zh) * 2003-09-23 2006-10-25 爱尔康公司 曲安奈德和醋酸阿奈可他注射用制剂
WO2005107705A2 (en) * 2004-04-30 2005-11-17 Allergan, Inc. Extended therapeutic effect ocular implant treatments
CN101119733A (zh) * 2005-02-18 2008-02-06 参天制药株式会社 减轻或避免甾族化合物副作用的方法

Also Published As

Publication number Publication date
UY31699A1 (es) 2009-05-29
AU2009223649A1 (en) 2009-09-17
BRPI0909630B1 (pt) 2019-03-26
AU2009223649B2 (en) 2013-08-29
RU2481842C2 (ru) 2013-05-20
US20120115829A1 (en) 2012-05-10
JP2011513492A (ja) 2011-04-28
EP2262506A1 (en) 2010-12-22
TW200940071A (en) 2009-10-01
PL2262506T3 (pl) 2014-09-30
EP2262506B1 (en) 2014-05-07
US8211880B2 (en) 2012-07-03
BRPI0909630B8 (pt) 2021-05-25
SI2262506T1 (sl) 2014-07-31
KR20100127267A (ko) 2010-12-03
WO2009114521A1 (en) 2009-09-17
MX2010009974A (es) 2010-09-30
BRPI0909630A2 (pt) 2015-09-22
CN101959519A (zh) 2011-01-26
US20090233890A1 (en) 2009-09-17
HK1146464A1 (en) 2011-06-10
DK2262506T3 (da) 2014-06-10
AR070824A1 (es) 2010-05-05
ES2471122T3 (es) 2014-06-25
JP5581227B2 (ja) 2014-08-27
PT2262506E (pt) 2014-06-24
RU2010141542A (ru) 2012-04-20
TWI468165B (zh) 2015-01-11
CL2009000573A1 (es) 2010-01-04
ZA201005839B (en) 2011-10-26
US8128960B2 (en) 2012-03-06
CA2717605C (en) 2012-05-15
US20120116216A1 (en) 2012-05-10
CA2717605A1 (en) 2009-09-17
KR101555293B1 (ko) 2015-10-06

Similar Documents

Publication Publication Date Title
CN101959519B (zh) 用于玻璃体内注射的低粘度、高度絮凝的曲安奈德混悬液
JP5732058B2 (ja) 眼科用水性注射可能組成物およびその使用方法
KR102498075B1 (ko) 주사용 제제
TWI624262B (zh) 醫藥配方
TW200528114A (en) Compositions and methods for treating a posterior segment of an eye
SA516380321B1 (ar) مستحضرات للعين لتوصيل الدواء إلى الجزء الخلفي من العين
US20050065137A1 (en) Triamcinolone acetonide and anecortave acetate formulations for injection
AU2004317520B2 (en) Stable injectable diclofenac compositions
KR102888598B1 (ko) 약물 전달을 위한 약학적 생분해성 겔
CN104721130B (zh) 一种布林佐胺包合物眼用制剂及其制备方法
HK1146464B (en) Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection
MXPA06005146A (en) Compositions and methods for treating a posterior segment of an eye

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20191128

Address after: Fribourg

Patentee after: ALCON, Inc.

Address before: Texas, USA

Patentee before: Alcon Research Co.,Ltd.

Effective date of registration: 20191128

Address after: Texas, USA

Patentee after: Alcon Research Co.,Ltd.

Address before: Texas, USA

Patentee before: ALCON RESEARCH, Ltd.

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20200824

Address after: Basel, Switzerland

Patentee after: NOVARTIS AG

Address before: Fribourg

Patentee before: ALCON, Inc.

TR01 Transfer of patent right